2006 Symposium Highlights
Translational Medicine and Therapeutics:
The Future of Drug Development
May 5- 6, 2006
-
The College of Integrated Life Sciences: an Academic Model for Fostering Translational Research
Edward Holmes, M.D., Vice Chancellor, UCSD (University of California, San Diego)
- αllb β3 Antagonists As An Example of Translational Medicine Therapeutics
Barry Coller, M.D., Physician in Chief, Rockefeller University
- Prescribing By Genotype Are We There Yet?
Alastair Wood, M.D., Associate Dean, Vanderbilt University School of Medicine
- Cell and Gene Therapies: Challenges in Developing Paradigms for Analyzing Novel Therapeutics
Kathy High, M.D., Ph.D., Investigator, HHMI, University of Pennsylvania School of Medicine
- The Emerging Era of Translational Medicine and Therapeutics
Garret FitzGerald, M.D., Director, ITMAT, Chair, Department of Pharmacology, University of Pennsylvania
- Translational Studies in Heart Failure
Walter Koch, Ph.D., Director, Center for Translational Medicine, Thomas Jefferson University
- Today's Discoveries, Tomorrows Cures? A Convergence of Cultures
Ellen Puré, Ph.D., Wistar and Ludwig Institutes
- Integrated Clinical Research Informatics for Translational Medicine and Therapeutics
J. Richard Landis, Ph.D., Professor of Biostatistics, University of Pennsylvania
- The Greater Philadelphia Bioinformatics Alliance: Technology Collaboration for Training and Discovery
J. Robert Beck, M.D., Vice President and Deputy Director of Population Science, Fox Chase Cancer Center
- Fostering Innovation: A Government Perspective
Mary Harney, TD, Tánaiste and Minister for Health and Children, Government of Ireland
- FDA’s Critical Path Initiative and Translational Research
Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA
- Revitalising Clinical Investigation, Who, How and Where?
Sir Colin Dollery, M.D., Senior Advisor, GlaxoSmithKline
- Making Pharma Sector Investment More Attractive – Why the Business Model Needs to Change?
Sophia Tickell BA, Director of Pharma Futures II, and Chair, SustainAbility
- Improving Drugs and Development by Technology Advancements
Thomas Caskey, M.D., Managing Director, Cogene Ventures
- VEGF Trap in Clinical Trials Today, and VelociGene Coupled with Veloclmmune for Drug Targets of Tomorrow
George Yancopoulis, M.D., Ph.D., Chief Scientific Officer, Regeneron
- Labors of Love: Science Serving The Public Good
Jerome Strauss, M.D., Ph.D., Dean VCU School of Medicine, Virginia Commonwealth University
» Top
